Idorsia Raises $630m For Daridorexant Launch And Pipeline Push

With the US filing of its non-sedative sleeping pill now imminent, the Swiss biotech is also adding to its war chest to advance Phase III drugs aprocitentan, clazosentan and lucerastat.